The nine-valent HPV vaccine is usually available to healthy people between the ages of 16 and 26. The HPV vaccine is a vaccine against human papillomavirus and consists of three types: bivalent, quadrivalent and nine-valent, which are recommended according to the vaccination instructions. In general, the bivalent vaccine is recommended for people aged 9-45 years, the quadrivalent vaccine is recommended for people aged 20-45 years, and the nine-valent vaccine is recommended for people aged 16-26 years. There is not enough clinical evidence in China to prove whether the HPV nine-valent vaccine has an effect on its antiviral effect when administered over the age of 26, and there is no age limit for vaccination in some European regions. If people over 26 years of age want to receive the nine-valent HPV vaccine, they can consult their doctor and receive the vaccine according to their doctor’s recommendation if they meet the criteria for vaccination in addition to their age, if there are no contraindications to vaccination after examination, and if the vaccine resources are sufficient in their area. In addition, the nine-valent HPV vaccine is more effective for women who are not sexually active. Vaccination when you are over 26 years old and have already had sex may affect the antiviral effect of the vaccine, and the original prevention rate cannot be achieved, and the meaning of vaccination is lost. If HPV infection is present in some patients and vaccination cannot have a therapeutic effect, it is recommended to consult the relevant doctor to clarify whether vaccination is possible. Pregnant women, breastfeeding women, those who are allergic to HPV vaccine components, those with immune dysfunction, and those over 45 years of age are advised to receive HPV vaccination with caution to avoid other adverse reactions.